Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Dezember 2021 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
22. Dezember 2021 16:01 ET | Quelle: Arcutis Biotherapeutics, Inc.

FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

FDA has set a target action date of July 29, 2022NDA supported by positive efficacy data from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety...
16. Dezember 2021 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
13. Dezember 2021 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

Data presented at Revolutionizing Atopic Dermatitis (RAD) ConferenceVehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from...
10. November 2021 08:02 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis to Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
04. November 2021 16:02 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of diseaseInitiated single pivotal Phase 3 trial of roflumilast foam in scalp...
04. Oktober 2021 08:00 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

Plaque psoriasis is a skin disease that affects approximately 8.6 million individuals in the U.S. and presents particular treatment challenges in certain anatomical regions.Roflumilast cream, a...
30. September 2021 08:30 ET | Quelle: Arcutis Biotherapeutics, Inc.

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as Phase 2 studies in seborrheic dermatitis and scalp and body...
28. September 2021 16:05 ET | Quelle: Arcutis Biotherapeutics, Inc.

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
27. September 2021 08:05 ET | Quelle: Arcutis Biotherapeutics, Inc.

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...

Vorherige Seite